$47.13
+0.35 (+0.75%)
Open$46.68
Previous Close$46.78
Day High$47.62
Day Low$44.27
52W High$51.91
52W Low$16.48
Volume—
Avg Volume545.3K
Market Cap2.24B
P/E Ratio—
EPS$-1.92
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
-46.8% upside
Current
$47.13
$47.13
Target
$25.06
$25.06
$14.18
$25.06 avg
$26.23
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 242.99M | 245.23M | 253.21M |
| Net Income | -48,406,908 | -45,232,819 | -47,387,261 |
| Profit Margin | -19.9% | -18.5% | -18.7% |
| EBITDA | -47,660,000 | -53,758,331 | -46,826,478 |
| Free Cash Flow | -27,352,313 | -27,764,891 | -38,614,891 |
| Rev Growth | +24.0% | +24.2% | +22.9% |
| Debt/Equity | 0.34 | 0.34 | 0.36 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |